Boston completes Prolieve acquisition:
This article was originally published in Clinica
Boston Scientific has closed its acquisition of Celsion's Prolieve technology for treating symptomatic benign prostatic hyperplasia. The two companies had agreed to the $60m transaction in April 2007 (see Clinica No 1253, p 12). Celsion will use the proceeds to fund its ThermoDox liver cancer drug programme.